Effectiveness

Patients often report increased vitality and improved general well-being shortly after the therapy.

In addition to the direct filtration of toxins and inflammatory markers, INUSpheresis^® also supports the microcirculation of the blood. As a result, tissues and organs are better supplied with oxygen and nutrients.

Studies have shown significant reductions in fibrinogen and homocysteine as well as a sustained reduction in lipids. Blood analyses before and after INUSpheresis^® treatment showed a significant reduction in inflammatory markers and metal concentrations in the body ^{16 17}.

Since its introduction, INUSpheresis^® has gained worldwide recognition, with over 50,000 therapies performed in 43 active centers. It is used exclusively by certified and trained specialists to ensure the highest quality and safety. INUSpheresis^® has been proven to lead to improvements in 17 different diseases.

Over 31,000 studies have investigated the diverse areas of application of therapeutic apheresis. A detailed data analysis based on the INUSpheresis^® SOP protocol has confirmed the effectiveness of the therapy and enabled a validated treatment protocol. This SOP protocol shows documented efficacy in 17 diseases.

Micro- and nanoparticles of different sizes and chemical compositions were found in the INUSpheresis^® filtrate (eluate). The concentrations of various metals in the eluate are particularly striking.

The table shows the average value of the analyzed eluate of the first and second INUSpheresis^® treatment. The gray bars represent the limit values.

Concentration (μg/l) of filtered metals in the eluate of the first and second INUSpheresis treatment (n = 6). The interval between treatments was one day. The limits were determined according to WHO criteria and the 75% percentile of INUS Laboratories from over 500 samples ¹⁸.

As part of scientific investigations, the eluate obtained by double filtration plasmapheresis (DFPP) was analyzed using techniques such as field emission scanning electron microscopy and energy dispersive X-ray spectroscopy (FE-SEM/EDX)¹⁹.

The graph shows that INUSpheresis^® effectively removes heavy metals from the blood, with the filtrate showing a lower load in most cases after the second application.

For example, the aluminum residues are almost 10 times higher than the WHO limits and the titanium residues are more than 6 times higher.

Why can't INUSpheresis filter all residues at once?

Pathogenic proteins and lipids are filtered directly. Heavy metals are primarily only present in the blood plasma in small quantities as they are deposited in cells. For efficient removal of heavy metals, 2 INUSpheresis^® treatments are used at intervals of 48-72 hours.

This means that substances that have been deposited in the tissue can also be removed and enter the plasma or the kidneys within 48 hours via post-mobilization and saturation compensation.

After more than a decade of research and development, INUSpheresis^® has been established in medicine since 2018. The scientific processing of the data on INUSpheresis^® and its results have been verified in a total of 12 medical publications to date. The device and filter set are ISO 13485:2016 certified.

Between 2006 and 2017, over 512,000 data points were collected and statistically analyzed in accordance with the INUSpheresis^® SOP protocol. This comprehensive data analysis enabled the validation and creation of a treatment protocol.